| Entry |
|
|---|
| Name |
COVID-19 vaccine (ChAdOx1-S [recombinant]);
ChAdOx1-SARS-COV-2;
Vaxzevria (TN) |
|---|
| Class |
|
|---|
| Remark |
| Therapeutic category: | 6313 |
|
|---|
| Efficacy |
Active immunization (SARS-CoV-2) |
|---|
| Disease |
Prevention of COVID-19 [DS: H02398] |
|---|
| Target |
SARS-CoV-2 spike glycoprotein [KO: K24152] |
|---|
| Pathway |
| ko05171 | Coronavirus disease - COVID-19 |
|
|---|
| Brite |
Therapeutic category of drugs in Japan [BR:br08301]
6 Agents against pathologic organisms and parasites
63 Biological preparations
631 Vaccines
6313 Viral vaccines
D12115 COVID-19 vaccine (ChAdOx1-S [recombinant])
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D12115
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D12115
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D12115
|
|---|
| LinkDB |
|
|---|
